Status: Recruiting
A Study of PLH-2301 in Subjects With Sarcopenia
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.
Participants needed: 168
Trial details
Phase: Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Pluto Inc.Updated: May 12, 2026Locations: 5
Eligibility criteria
Male or female subjects aged 65 years or older at the time of consent [+6]
History of clinically significant neuromuscular or musculoskeletal disorders tha... [+4]